Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma

Hye Ryun Kim, Seong Ha Cheon, Kwang Hun Lee, Jung Ryun Ahn, Hei Cheul Jeung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: Optimal treatment for liver metastases from gastric cancer remains a matter of debate. The aim of our study is to evaluate the efficacy of radiofrequency ablation (RFA) for the treatment of liver-only metastases from gastric adenocarcinoma. Materials and methods: We retrospectively reviewed medical records of 29 patients who developed liver-only metastases from gastric adenocarcinoma and subsequently underwent gastric resection and RFA (n 20) or gastric resection and systemic chemotherapy (n 9) between January 1995 and February 2008. Overall survival was estimated using the Kaplan-Meier method, and was compared using the log rank test to evaluate RFA efficacy. Results: Twenty patients who underwent RFA showed a median overall survival of 30.7 months (range: 2.9 to 90.9 months), a median progression-free survival of 6.8 months (range: 0.8 to 45.2 months), and median overall one-, three-, and five-year survival rates were 66.8, 40.1, and 16.1 respectively. The RFA group showed a 76 decreased death rate compared to the chemotherapy-only group (30.7 months versus 7 months, hazard ratio, 0.24; p 0.004). Most patients tolerated RFA well, and complications were found to be minor (transient fever (20) and/or right upper quadrant pain (25)). One case of treatment-related death occurred due to sepsis that originated from a liver abscess at the ablation site. Conclusions: The data suggest that a use of RFA as a liver-directed treatment may provide greater survival benefit than chemotherapy and is an alternative option for the treatment of liver-only metastases from gastric cancer.

Original languageEnglish
Pages (from-to)305-315
Number of pages11
JournalInternational Journal of Hyperthermia
Volume26
Issue number4
DOIs
Publication statusPublished - 2010 May 26

Fingerprint

Stomach
Adenocarcinoma
Neoplasm Metastasis
Liver
Drug Therapy
Stomach Neoplasms
Survival
Therapeutics
Liver Abscess
Disease-Free Survival
Medical Records
Sepsis
Fever
Survival Rate
Pain
Mortality

All Science Journal Classification (ASJC) codes

  • Physiology
  • Physiology (medical)
  • Cancer Research

Cite this

Kim, Hye Ryun ; Ha Cheon, Seong ; Lee, Kwang Hun ; Ryun Ahn, Jung ; Jeung, Hei Cheul ; Sook Lee, Sung ; Cheol Chung, Hyun ; Hoon Noh, Sung ; Young Rha, Sun. / Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. In: International Journal of Hyperthermia. 2010 ; Vol. 26, No. 4. pp. 305-315.
@article{7d23cbadf149437d971f591c1e74ae96,
title = "Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma",
abstract = "Purpose: Optimal treatment for liver metastases from gastric cancer remains a matter of debate. The aim of our study is to evaluate the efficacy of radiofrequency ablation (RFA) for the treatment of liver-only metastases from gastric adenocarcinoma. Materials and methods: We retrospectively reviewed medical records of 29 patients who developed liver-only metastases from gastric adenocarcinoma and subsequently underwent gastric resection and RFA (n 20) or gastric resection and systemic chemotherapy (n 9) between January 1995 and February 2008. Overall survival was estimated using the Kaplan-Meier method, and was compared using the log rank test to evaluate RFA efficacy. Results: Twenty patients who underwent RFA showed a median overall survival of 30.7 months (range: 2.9 to 90.9 months), a median progression-free survival of 6.8 months (range: 0.8 to 45.2 months), and median overall one-, three-, and five-year survival rates were 66.8, 40.1, and 16.1 respectively. The RFA group showed a 76 decreased death rate compared to the chemotherapy-only group (30.7 months versus 7 months, hazard ratio, 0.24; p 0.004). Most patients tolerated RFA well, and complications were found to be minor (transient fever (20) and/or right upper quadrant pain (25)). One case of treatment-related death occurred due to sepsis that originated from a liver abscess at the ablation site. Conclusions: The data suggest that a use of RFA as a liver-directed treatment may provide greater survival benefit than chemotherapy and is an alternative option for the treatment of liver-only metastases from gastric cancer.",
author = "Kim, {Hye Ryun} and {Ha Cheon}, Seong and Lee, {Kwang Hun} and {Ryun Ahn}, Jung and Jeung, {Hei Cheul} and {Sook Lee}, Sung and {Cheol Chung}, Hyun and {Hoon Noh}, Sung and {Young Rha}, Sun",
year = "2010",
month = "5",
day = "26",
doi = "10.3109/02656730903555696",
language = "English",
volume = "26",
pages = "305--315",
journal = "International Journal of Hyperthermia",
issn = "0265-6736",
publisher = "Informa Healthcare",
number = "4",

}

Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. / Kim, Hye Ryun; Ha Cheon, Seong; Lee, Kwang Hun; Ryun Ahn, Jung; Jeung, Hei Cheul; Sook Lee, Sung; Cheol Chung, Hyun; Hoon Noh, Sung; Young Rha, Sun.

In: International Journal of Hyperthermia, Vol. 26, No. 4, 26.05.2010, p. 305-315.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma

AU - Kim, Hye Ryun

AU - Ha Cheon, Seong

AU - Lee, Kwang Hun

AU - Ryun Ahn, Jung

AU - Jeung, Hei Cheul

AU - Sook Lee, Sung

AU - Cheol Chung, Hyun

AU - Hoon Noh, Sung

AU - Young Rha, Sun

PY - 2010/5/26

Y1 - 2010/5/26

N2 - Purpose: Optimal treatment for liver metastases from gastric cancer remains a matter of debate. The aim of our study is to evaluate the efficacy of radiofrequency ablation (RFA) for the treatment of liver-only metastases from gastric adenocarcinoma. Materials and methods: We retrospectively reviewed medical records of 29 patients who developed liver-only metastases from gastric adenocarcinoma and subsequently underwent gastric resection and RFA (n 20) or gastric resection and systemic chemotherapy (n 9) between January 1995 and February 2008. Overall survival was estimated using the Kaplan-Meier method, and was compared using the log rank test to evaluate RFA efficacy. Results: Twenty patients who underwent RFA showed a median overall survival of 30.7 months (range: 2.9 to 90.9 months), a median progression-free survival of 6.8 months (range: 0.8 to 45.2 months), and median overall one-, three-, and five-year survival rates were 66.8, 40.1, and 16.1 respectively. The RFA group showed a 76 decreased death rate compared to the chemotherapy-only group (30.7 months versus 7 months, hazard ratio, 0.24; p 0.004). Most patients tolerated RFA well, and complications were found to be minor (transient fever (20) and/or right upper quadrant pain (25)). One case of treatment-related death occurred due to sepsis that originated from a liver abscess at the ablation site. Conclusions: The data suggest that a use of RFA as a liver-directed treatment may provide greater survival benefit than chemotherapy and is an alternative option for the treatment of liver-only metastases from gastric cancer.

AB - Purpose: Optimal treatment for liver metastases from gastric cancer remains a matter of debate. The aim of our study is to evaluate the efficacy of radiofrequency ablation (RFA) for the treatment of liver-only metastases from gastric adenocarcinoma. Materials and methods: We retrospectively reviewed medical records of 29 patients who developed liver-only metastases from gastric adenocarcinoma and subsequently underwent gastric resection and RFA (n 20) or gastric resection and systemic chemotherapy (n 9) between January 1995 and February 2008. Overall survival was estimated using the Kaplan-Meier method, and was compared using the log rank test to evaluate RFA efficacy. Results: Twenty patients who underwent RFA showed a median overall survival of 30.7 months (range: 2.9 to 90.9 months), a median progression-free survival of 6.8 months (range: 0.8 to 45.2 months), and median overall one-, three-, and five-year survival rates were 66.8, 40.1, and 16.1 respectively. The RFA group showed a 76 decreased death rate compared to the chemotherapy-only group (30.7 months versus 7 months, hazard ratio, 0.24; p 0.004). Most patients tolerated RFA well, and complications were found to be minor (transient fever (20) and/or right upper quadrant pain (25)). One case of treatment-related death occurred due to sepsis that originated from a liver abscess at the ablation site. Conclusions: The data suggest that a use of RFA as a liver-directed treatment may provide greater survival benefit than chemotherapy and is an alternative option for the treatment of liver-only metastases from gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=77952471110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952471110&partnerID=8YFLogxK

U2 - 10.3109/02656730903555696

DO - 10.3109/02656730903555696

M3 - Article

C2 - 20210605

AN - SCOPUS:77952471110

VL - 26

SP - 305

EP - 315

JO - International Journal of Hyperthermia

JF - International Journal of Hyperthermia

SN - 0265-6736

IS - 4

ER -